Trial Profile

Retrospective cohort study of tixagevimab and cilgavimab in adults with a primary immunodeficiency

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 28 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cilgavimab/tixagevimab (Primary)
Indications COVID 2019 infections
Focus Therapeutic Use

Most Recent Events

28 Dec 2022 New trial record
14 Nov 2022 Results comparing the incidence of Covid-infections in adults with primary immunodeficiency who received tixagevimab and cilgavimab to adults who did not receive tixagevimab and cilgavimab presented at the 2022 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com